Biologics Outsourcing Market Analysis

Biologics Outsourcing Market Analysis

To get key market trends

  Download Free Sample

By product, the biologics outsourcing market is classified into antibodies, vaccines, cell and gene therapeutics, recombinant proteins, blood and blood products, and other biologics. The antibodies accounted for 60.9% market share in 2022. Antibodies are utilized as therapeutic agents to target specific disease-causing molecules, aiding in the treatment of various conditions like cancer, autoimmune diseases, and infectious diseases.
 

Antibodies are widely used for target validation, characterization, and quantification of proteins during the drug discovery, development process and various other applications. These antibodies enable researchers to understand the role and function of these targets in disease progression and aid in the identification of potential target therapeutics. Furthermore, outsourcing of antibodies helps the companies to focus on their core competencies, such as drug discovery, pre-clinical and clinical research and various other R&D activities, while ensuring compliance with regulations and reducing regulatory risks.
 

Based on service, the biologics outsourcing market is segmented into analytical testing, process development, cell development, cGMP manufacturing, and other services. The cell development segment accounting for USD 4.2 billion in 2022 and is anticipated to witness high growth at a CAGR of 15.8% by 2032 attributed to several factors such as advancements in cell engineering technologies, the need for cost-effective and efficient manufacturing processes, and the rising trend of outsourcing cell development services. Furthermore, with the increasing demand for biologic therapies and the complexity involved in their development, pharmaceutical and biotechnology companies are increasingly relying on outsourcing partners specializing in cell development services.
 

Based on source, the biologics outsourcing market is segmented into mammalian and microorganisms. The mammalian segment is expected to witness notable expansion to reach USD 62.8 billion by 2032. Outsourcing to CDMOs with extensive experience in mammalian cell culture ensures that the desired protein modifications are accurately replicated, enhancing the safety and efficacy of the final desired product. Additionally, mammalian cell culture systems offer scalability, allowing for flexible manufacturing capacity to meet varying production demands.
 

Based on application, the biologics outsourcing market is segmented into Oncology, immunological disorders, infectious diseases, vaccine development, cell and gene therapy, blood related product development, stem cell research, and other applications. The oncology segment held a market share of 30.1% in 2022 and is anticipated to progression at a CAGR of 15.5% by 2032. Biologics offer targeted and personalized approaches to cancer treatment, making them highly effective in combating various types of malignancies. With an increasing number of pharmaceutical companies focusing on oncology drug development, the need for outsourcing services in this segment is expected to surge.
 

Based on end-user, the biologics outsourcing market is segmented into pharmaceutical and biopharmaceutical companies and biotechnological companies. The biotechnological company’s segment is projected to grow at a CAGR of 15.3% by 2032 attributed to advancements in biotechnology research and development that has increased demand for biologics outsourcing services. These companies are turning to specialized service providers to capitalize on their expertise allowing them to focus on their core competencies. Biotechnological companies, both large and small, are leveraging outsourcing partnerships to streamline their operations, accelerate time-to-market, and enhance their competitive edge.
 

North America region held a significant biologics outsourcing market share of 46.3% in 2022 and is projected to expand at 12.2% CAGR by 2032. The region's robust healthcare infrastructure, cutting-edge research and development facilities, and a strong emphasis on innovation have contributed to this upward trajectory. The increasing demand for biologics, including monoclonal antibodies, vaccines, and cell therapies, coupled with the high cost of in-house manufacturing, has driven pharmaceutical and biotechnology companies to outsource their biologic production processes. Additionally, North America's strategic geographic location and the availability of highly skilled workforce has made it an attractive destination for biologics outsourcing. The region's emphasis on quality control, adherence to stringent regulatory standards, and efficient supply chain management.